Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Japan’s 1st Enbrel Biosimilar Makes Its Debut
Japan’s first Enbrel (etanercept) biosimilar hit the market on May 30 upon its price listing the same day, Mochida Pharmaceutical and its partner Ayumi Pharmaceutical said. The Enbrel biosimilar was launched in five specifications (two vial versions, two prefilled syringe…
To read the full story
Related Article
- Ayumi Chief Says Contender Debut Will Add Vigor to Enbrel Biosimilar Space, Sees Govt Fee Incentive as Booster
June 23, 2020
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand
October 19, 2018
- Mochida’s Enbrel Biosimilar Approved, with Ayumi as Distributor
January 22, 2018
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…